TY - JOUR
T1 - Importance of bone turnover for therapeutic decisions in patients with CKD-MBD
AU - Ott, Susan M.
AU - Malluche, Hartmut H.
AU - Jorgetti, Vanda
AU - Elder, Grahame J.
N1 - Publisher Copyright:
© 2021 International Society of Nephrology
PY - 2021/9
Y1 - 2021/9
N2 - Patients with chronic kidney disease–mineral and bone disorder (CKD-MBD) frequently have low bone formation rates. A recent review suggested that adynamic bone disease is not always associated with negative outcomes and therefore antiresorptive medications could be used more often. However, there is currently no evidence to support an improvement in fracture risk or mortality in patients with CKD-MBD and low bone turnover who are treated with antiresorptive medication. There is reasonable pathophysiological evidence suggesting that it may even be harmful.
AB - Patients with chronic kidney disease–mineral and bone disorder (CKD-MBD) frequently have low bone formation rates. A recent review suggested that adynamic bone disease is not always associated with negative outcomes and therefore antiresorptive medications could be used more often. However, there is currently no evidence to support an improvement in fracture risk or mortality in patients with CKD-MBD and low bone turnover who are treated with antiresorptive medication. There is reasonable pathophysiological evidence suggesting that it may even be harmful.
UR - http://www.scopus.com/inward/record.url?scp=85112390915&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112390915&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2021.05.024
DO - 10.1016/j.kint.2021.05.024
M3 - Comment/debate
C2 - 34420656
AN - SCOPUS:85112390915
SN - 0085-2538
VL - 100
SP - 502
EP - 505
JO - Kidney International
JF - Kidney International
IS - 3
ER -